HITIQ presentation - Bioshares Biotech Summit
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
25 JULY 2023
HITIQ PRESENTS AT BIOSHARES BIOTECH SUMMIT
Transformative, concussion management technology company, HITIQ Limited (ASX: HIQ) (HITIQ or the Company),
is pleased to advise that Damian Hawes, Chief Commercial Officer of HITIQ, will be presenting at the
17th Bioshares Biotech Summit in Hobart, Tasmania, today 25 July 2023.
The Bioshares Biotech Summit’s unique format brings together biotechnology companies and fund managers,
stockbrokers and investment bankers active in the sector as well as retail investors who have a committed interest
in biotech stocks or are looking to build their knowledge and networks in this space.
A distinguishing feature of the Summit is that companies are asked not to present a standard pitch deck, but to
present on themes that provide an opportunity for investors to gain a deeper understanding on each company’s
business, challenges and opportunities.
Given the significant media and community interest, along with emerging evidence of a link between head impact
exposure and Chronic Traumatic Encephalopathy (CTE), the Company is delighted to outline our approach as the
global leader in concussion and brain health technologies in sport.
A copy of the presentation is attached.
- ENDS –
Authorised for release by the Board of Directors.
For more information, contact:
Mike Vegar
CEO & MD
HITIQ Limited
investors@hitiq.com
About HITIQ
HITIQ Limited (ASX: HIQ) operates in the healthcare equipment sector, providing and further developing a transformative, end-to-end
concussion management technology platform. This platform aims to provide a total concussion ecosystem whereby the Company’s products
support the identification, monitoring and management of sport related brain injury. HITIQ’s product suite utilises high-end technology that
will span multiple domains – from early detection and surveillance to assessment and rehabilitation technology tools.
HITIQ is targeting a growing worldwide concussion management market including elite and recreational sport, clinical practitioners, military,
research, and combat sports. The Company’s first commercial partner is the Australian Football League, with current strategy initiatives
expanding commercially into Rugby League, Rugby Union, Ice Hockey, Lacrosse, MMA and American Football (particularly the NCAA). The
market opportunity globally represents ~500k athletes within the elite market and ~10million in the consumer market. 1
Bioshares BioTech Summit
25th July 2023
Damien Hawes
Chief Commercial Officer
Disclaimer
This presentation has been prepared by HITIQ Limited (HIQ) and is provided for general information purposes only. No party other than HITIQ has authorised or caused
the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.
This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial
situation or needs of any particular investor. HITIQ makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the
information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even
elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are
subject to change without notice. HITIQ and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of
negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any
omissions from this presentation, except liability under statute that cannot be excluded.
This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer,
invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom,
such an offer would be illegal.
This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties
and assumptions, many of which are outside the control of HITIQ. Actual values, results or events may be materially different to those expressed or implied in this
presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No
representation or warranty (express or implied) is made by HITIQ or any of its directors, officers, employees, advisers or agents that any forecasts, projections,
intentions, expectations or plans set out in this presentation will be achieved.
Overview
1.
Capital Structure
2.
Supported by World-Leading Advisors
3.
About
4.
The Challenge
5.
Global Trends and Increased Concussion Awareness
4.
Product Suite
5.
Global Data Collection
6.
Strategies for Accelerating Adoption
7.
Addressable Market
8.
Key Points
Capital Structure
Shareholders
Capital Structure (21 July 2023)
ASX Code
HIQ
Share Price
$0.024
Shares on Issue
266.8 M
Unlisted Option ($0.04, Exp Dec 23’)
134.3 M
Market Capitalisation
$6.40 M
Cash in Bank (31 Mar 2023)
$2.04 M
Directors & Managers
14%
Top 20
55%
31%
Others
Board of Directors
Otto Buttula
Mike Vegar
Aidan Clarke
Glenn Smith
Phil Carulli
Non-Executive Chairman
Managing Director
Non-Executive Director
Non-Executive Director
Non-Executive Director
‣ Extensive financial, investment, IT &
‣ Co-Founder of HIQ and led company
biotech experience
since inception
‣ Executive Chairman of Rhythm (ASX: RHY) ‣ Extensive experience across elite
sports (AIS)
‣ Co-Founder and CEO of IWL (ASX: IWL)
‣ Founder/former CEO of Investors Mutual ‣ Co-Founded Australian leading
mouthguard manufacturing business
‣ Former Director of Imugene (ASX:IMU) &
Chairman of Investor First (ASX: HUB)
‣ Chairman of Oncosil Medical (ASX: OSL)
‣ Co-Founder of 2XU
‣ Sales & Marketing Director leading 2XU
to $100m revenue line
‣ Vast sales distribution networks globally,
particularly in USA
‣ Founder of SA1NT Group
‣ Multi-decade career in technology
‣ Chartered Accountant & Managing Director
commercialisation, international expansion of Optima Partners
& Health technology.
‣ HIQ non-executive director & CFO since
‣ Co-Founder & Investment Director of
August 2018
Aruma Capital ($50m VC Fund)
‣ Non-Executive Director of Soar-Earth
‣ Chairman & Investor at HealthcareLink
Limited
‣ Former Director of StartupAUS (now Tech ‣ Experienced investor, capital raising,
Council) & GM Resonance Health (ASX:RHT) corporate compliance & governance
Supported by World-Leading Advisors
Scientific & Medical Advisory Council (SMAC)
Honorary Associate Professor
Andrew Gardner
University of Newcastle, AUS
Professor
Carolyn Emery
University of Calgary, CAN
Emeritus Professor
Jeffrey V. Rosenfeld AC OBE
Monash University, AUS
‣
‣ Professor, Faculty of Kinesiology,
Canadian Institutes of Health Research
Canada Research Chair (Tier 1)
Concussion
‣ Chair, Sports Injury Prevention
Research Centre, University of Calgary
‣ Experienced senior neurosurgeon at
Alfred Hospital, Melbourne
‣ Emeritus professor of surgery at
Monash University, Melbourne
Doctor
Robby Sikka
USA
Assistant Professor
Doug Terry
Vanderbilt University, USA
Doctor
Joshua Goldman
UCLA, USA
‣
‣
‣
‣
‣
Research Fellow, School of Medicine
and Public Health, College of Health,
Medicine, and Wellbeing, The
University of Newcastle
Clinical Neuropsychologist, Hunter
New England Local Health District,
Newcastle
New York Yankees Team Physician
CEO of Sports Medicine Analytics
Research Team (SMART)
‣
Neuropsychologist at Vanderbilt
University Medical Center in
Nashville, TN, USA
Director of the Center for Cognitive
Neurosurgical Studies at Vanderbilt
University in Nashville, TN.
Assistant Clinical Professor,
Departments of Family Medicine and
Orthopaedic Surgery, UCLA
About
We are the global leader in concussion & brain health
technologies in sport.
We will eliminate the risk of undetected and unmanaged head impacts through data driven solutions.
Technology
Platform
Surveillance
Quantify head
impact exposure
Assessment
Record & store
incident data
Diagnosis
Define
impairment
The Challenge - What is CTE?
There is emerging evidence of a link between head impact exposure and Chronic
Traumatic Encephalopathy (CTE), a degenerative brain disease.
The largest study on CTE in American Football
players estimates that for every 1,000 head
impacts CTE risk increases by ~20%.
HIT•IQ technologies provide the
solution for collecting accurate data
to measure, manage, and mitigate
head impacts.
Global Trends and Increased Concussion Awareness
An Australian Senate inquiry into concussion and repeat head trauma
in contact sports has been conducted.
Chief Medical Officers from major sports codes have now acknowledged the link between
chronic head impact exposure and CTE/Neurodegenerative diseases.
Senate inquiry findings due in August are likely to accelerate the
adoption of technologies across codes and consumer pathways.
Litany of legal cases emerging.
Nexus
The Nexus Instrumented Mouthguard accurately captures the
frequency and intensity of head impacts.
15,000 datapoints per second.
Bluetooth enabled, near-real time data transfer with
wireless charging & six-hour battery life.
Integrated world-class hardware & software solution.
Laboratory
Testing
On-field
Classification Performance
98%
98%
93%
Accuracy
Sensitivity
Specificity
ConneQt
An integrated solution linking team managers, players, guardians and
specialised physicians - delivering accessible concussion care.
Digital Incident Reports
Automated Alerts
24-hour Telehealth Access
Comprehensive Analytics
The highest standard of sport-related concussion care.
CoVR
Assessing cognitive performance with VR (Virtual Reality).
Traditional pen and paper or iPad-based testing used for baseline or
post injury assessments lack specificity and are prone to malingering.
Comprehensive, Multi-modal Assessment
Immersive, Gamified Experience
Increased Sensitivity
Pre-clinical testing underway: 500 participants tested across
normative and concussed cohorts from pre-clinical testing sites.
Global Data Collection
The largest global databank of head impacts and concussion assessments
captured over 7 years.
40k Athletes Monitored
490k+ Impacts Captured
130k+ Cognitive Assessments
Player Head Impact Passports
Third Party Risk Model Development
Informing OH&S Policy
Strategies for Accelerating Adoption
Data from partnerships providing a gateway to both elite &
consumer markets, underpinning our commercial strategy.
North America Elite
Partnership with
12 x NCAA D1 Football Programs
Partnerships have delivered:
North America Consumer
Collaboration with
Shock Doctor, Inc
World leading consumer mouthguard manufacturer:
✓ 70,000 impacts captured and foundational
data set established.
✓ Unparalleled manufacturing and distribution network, with
access to over 20,000 global retail outlets.
✓ Demonstrated technology fit in target
market.
✓ Final stages of a co-developed over-the-counter
instrumented mouthguard underway.
Addressable Markets
Significant global opportunity across multiple segments including
elite, consumer and allied health.
Teams/
Accounts
Athletes
Nexus
ConneQt/CSX
CoVR
HIT•IQ Technology Adopted by:
Elite Sport
10k
500k
$310m
$28m
Consumer
110k
11m
$3.6Bn
$77m
$100m
Military
Australian Rules Football
Rugby Union, League
Allied Health
300k
$1.5Bn
$3Bn
$1.61Bn
$3.1Bn
American Football
Soccer, Cricket, Lacrosse
Addressable Market
$3.91Bn
MMA, Boxing
Key Points
‣
Link between CTE and repeat head impact exposure can’t be ignored.
‣
Escalating need for sporting codes to invest in objective, data led technology solutions to meet
duty of care obligations.
‣
Unmet needs across $8B addressable market.
‣
Global leadership position in data driven solutions to prioritise and preserve brain health.
‣
Foundations built in key target markets.
Share your feedback
Discover